Travaux scientifiques

Uzm. Dr. Ece Ulukal Karancı

19 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-44980-w PMID 41888201 Texte intégral en libre accèsSource : OpenAlex

  2. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e24144 Source : OpenAlex

  3. The Prognostic Significance of the NOLUS Score in Patients with Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor Therapy

    Acta Medica Alanya, 2026

    DOI 10.30565/medalanya.1842660 Texte intégral en libre accèsSource : ORCID

  4. Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-63952-8 Texte intégral en libre accèsSource : ORCID

  5. Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124726 PMID 42355893 Texte intégral en libre accèsSource : ORCID

  6. Prediction of pathological complete response after neoadjuvant treatment in triple negative breast cancer: a single center experience

    Pamukkale Medical Journal, 2026

    DOI 10.31362/patd.1707522 Texte intégral en libre accèsSource : ORCID

  7. Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s570548 PMID 41930183 Texte intégral en libre accèsSource : OpenAlex

  8. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source : OpenAlex

  9. 560eP Early neutropenia does not predict survival in older patients treated with CDK4/6 inhibitors: A real-world analysis

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.107581 Texte intégral en libre accèsSource : OpenAlex

  10. Effect of "watch and wait" on fear of recurrence in rectal cancer: A multicenter cross-sectional study.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.12116 Texte intégral en libre accèsSource : OpenAlex

  11. Possible Ribociclib-Associated Focal Nodular Hyperplasia–Like Lesion Mimicking Liver Metastasis in a Chemotherapy-Naïve Patient: First Case Report

    Cancer Research and Treatment, 2026

    DOI 10.4143/crt.2026.0178 PMID 42526851 Texte intégral en libre accèsSource : OpenAlex

  12. Prognostic impact of primary tumor location in patients undergoing curative resection for colon cancer

    The Atlantic Journal of Medical Science and Research, 2026

    DOI 10.5455/atjmed.2026.02.015 Texte intégral en libre accèsSource : OpenAlex

  13. Prognostic Value of Systemic Inflammation Markers and Clinical Factors in Grade 4 Diffuse Glioma: A Multicenter Retrospective Real-World Study

    Cancers, 2026

    DOI 10.3390/cancers18193192 PMID 42882885 Texte intégral en libre accèsSource : OpenAlex

  14. The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol

    Expert Review of Anticancer Therapy, 2025

    DOI 10.1080/14737140.2025.2555467 PMID 40883857 1 citation (Europe PMC) Source : OpenAlex

  15. 2836P The effect of ribociclib dose reduction on progression-free survival in hormone receptor positive and HER-2 negative metastatic breast cancer: A multicenter study

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3448 Texte intégral en libre accèsSource : OpenAlex

  16. Symptom Reporting Behaviors, Symptom Burden, and Quality of Life in Patients with Hormone Receptor–Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32110599 PMID 41294660 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  17. The correlation of vitamin D level with the disease etiology and disease level in patients with chronic liver disease The correlation of vitamin D level with the disease etiology in with chronic liver disease

    Annals of Clinical and Analytical Medicine, 2021

    DOI 10.4328/acam.20721 Texte intégral en libre accèsSource : ORCID

  18. NSAID, antiaggregant, and/or anticoagulant-related upper gastrointestinal bleeding: Is there any change in prophylaxis rate after a 10-year period?

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2019

    DOI 10.5152/tjg.2019.19057 PMID 31199288 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  19. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study

    Supportive Care in Cancer, 2015

    DOI 10.1007/s00520-014-2531-6 PMID 25433439 16 citations (Europe PMC) Source : ORCID